Shanghai, China

Zhengtao Li

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 8.2

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2020-2022

Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: Inventor Zhengtao Li: Innovations in Pharmaceutical Compounds

Introduction

Zhengtao Li is an accomplished inventor based in Shanghai, China, with a remarkable portfolio of four patents. His work primarily focuses on developing innovative pharmaceutical compounds with significant implications for cancer treatment.

Latest Patents

His recent patents include groundbreaking inventions such as the ErbB/BTK inhibitors, which disclose compounds that inhibit ErbB family proteins, particularly mutant forms of these proteins, and Bruton's tyrosine kinase (BTK). These compounds, along with their pharmaceutical compositions, have shown effectiveness in treating diseases associated with ErbBs and BTK, especially in the context of cancer. Another notable patent involves ERBB receptor inhibitors, which consist of quinazoline compounds that inhibit ErbBs, including HER2. This invention also holds promise for treating diseases linked to ErbBs, particularly in oncology.

Career Highlights

Throughout his career, Zhengtao Li has made significant contributions to the field of pharmaceutical research. He has been associated with known pharmaceutical companies, such as Dizal Pharmaceutical Co., Ltd., where he applied his expertise to develop new therapeutic options.

Collaborations

Zhengtao has collaborated with esteemed colleagues, including Honchung Tsui and Zhenfan Yang, further enhancing the impact of his work in the innovative landscape of medicinal chemistry.

Conclusion

Zhengtao Li continues to be a pioneering force in the development of pharmaceuticals, focusing on revolutionary treatments for cancer. His patents reflect his dedication to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…